Differences in knowledge and attitudes toward the intrauterine device: Do age and race matter?

Knowledge gaps and information needs and preferences regarding oral contraceptive pills and over-the-counter access: A focus group study with Black and Latinx young people assigned female at birth

OBJECTIVE

On July 13, 2023, the Food and Drug Administration (FDA) approved a progestin-only oral contraceptive pill (OCP) for over-the-counter (OTC) use without an age restriction. Prior to this approval, we launched a qualitative study with Black and Latinx young people to inform access to an OTC OCP. Here we present findings related to knowledge gaps and information needs and preferences.

STUDY DESIGN

From April 26 to July 27, 2023, we held eight in-person focus groups (prior to the FDA approval) and one virtual focus group (after the FDA approval) with 65 pregnancy-capable young people aged 15-24 years (median 18 years) who identified as Black and/or Latinx. Community partners in Los Angeles, CA, Syracuse, NY, and Jackson, MS recruited participants from youth-serving programs and via social media. Authors double-coded focus group transcripts and analyzed the data thematically.

RESULTS

Participants largely did not know that an OTC OCP was possible. Many participants wanted to learn about an OTC OCP from health care providers and consult with a provider for follow-up as needed. Participants wanted to know about effectiveness and side effects, including at point-of-sale. Some participants had misconceptions about the safety of OCPs in general.

CONCLUSIONS

Findings suggest that Black and Latinx young people want information about an OTC OCP from providers. Providers can help support equitable access to an OTC OCP by educating young people about OTC availability and the safety and effectiveness of this option regardless of cost or location. Such education can address broader misconceptions about OCPs.

IMPLICATIONS

Results can inform efforts to increase awareness of an OTC OCP among Black and Latinx young people. Health care providers should provide information about effectiveness and side effects of this option.

Claims for Contraceptive Services and Chlamydia and Gonorrhea Testing Among Insured Adolescent and Young Adult Females in the United States

Objective: To examine claims for reversible prescription contraceptives and chlamydia and gonorrhea testing among commercially and Medicaid-insured adolescent and young adult (AYA) females in the United States. Methods: Using IBM MarketScan Research Databases, we identified sexually active, nonpregnant AYA (15- to 24-year-old) females enrolled in 2018. We examined claims for reversible prescription contraceptives and chlamydia and gonorrhea testing, using drug names and diagnosis/procedure codes, by age-group in commercially and Medicaid-insured separately and by race/ethnicity in Medicaid-insured. Results: Among 15- to 19-year-old and 20- to 24-year-old females, 67.2% and 67.9% of commercially insured and 57.3% and 54.0% of Medicaid-insured, respectively, had claims for reversible prescription contraceptives in 2018. Across insurance types among both age-groups, the most common claim for contraceptives was prescription for combined oral contraceptives. Among Medicaid-insured 15- to 19-year-olds, claims for contraceptives ranged from 42.6% for Hispanic females to 63.4% for non-Hispanic White females; among Medicaid-insured 20- to 24-year-olds, claims ranged from 50.4% for non-Hispanic Black females to 57.0% for non-Hispanic White females. Approximately half of the commercially and Medicaid-insured females had claims for chlamydia and gonorrhea testing. Non-Hispanic Black females had the highest percentages of claims for chlamydia testing (56.3% among 15- to 19-year-olds and 61.1% among 20- to 24-year-olds) and gonorrhea testing (61.6% among 15- to 19-year-olds and 64.9% among 20- to 24-year-olds). Conclusion: Approximately, two-thirds of commercially insured and more than half of Medicaid-insured, sexually active, nonpregnant AYA females had claims for reversible prescription contraceptives. Race/ethnicity data were available for Medicaid-insured females, and there were differences in claims for contraceptives and chlamydia and gonorrhea testing by race/ethnicity. Half of the AYA females had claims for chlamydia and gonorrhea testing suggesting missed opportunities.

Can an online educational video broaden young women's contraceptive choice? Outcomes of the PREFER pre-post intervention study

INTRODUCTION

Contraceptive knowledge mediates access and use. We aimed to assess whether an online educational video describing all methods and their benefits, side effects and mode of action increased young women's contraceptive knowledge and their long-acting reversible contraception (LARC) preference and uptake.

METHOD

We used Facebook advertising to recruit young women aged 16-25 years. Participants completed the pre-video survey (S1), watched the 11-min video, then completed surveys immediately after (S2) and 6 months later (S3). Outcomes were analysed using McNemar tests and multivariate logistic regression (generalised estimating equations).

RESULTS

A total of 322 participants watched the video, completed S1 and S2, and 88% of those completed S3. At S1 only 6% rated their knowledge about every method as high. Knowledge improved at S2 for all methods (OR 10.0, 95% CI 5.9 to 17.1) and LARC (OR 4.2, 95% CI 3.1 to 5.7). LARC preference increased at S2 (OR 1.7, 95% CI 1.4 to 2.1) and S3 (OR 1.4, 95% CI 1.2 to 1.7), as did LARC uptake at S3 (OR 1.3, 95% CI 1.11 to 1.5). LARC uptake was driven by a 4.3% (n=12) absolute increase in intrauterine device (IUD) use, but there was no change in contraceptive implant use (p=0.8). The use of non-prescription methods such as condoms and withdrawal did not change (OR 0.92, 95% CI 0.76 to 1.11).

CONCLUSIONS

Many young women in Australia do not feel well informed about their contraceptive options. The contraceptive education video, delivered via social media, increased their self-reported contraceptive knowledge and IUD preference immediately after viewing, and their IUD uptake 6 months later. Focus should be given to how young women navigate contraceptive access after internet-based education, and strategies to increase access to preferred methods.